Email Us
Call Us
AUSTIN, Texas – June 8, 2020 – Altogen Labs, a highly reputable GLP-compliant contract research organization (CRO) headquartered in Austin, Texas, today reaffirmed the full availability of its preclinical efficacy and in vivo toxicology services to pharmaceutical, biotechnology, and academic clients worldwide. As announced through Business Wire in May 2020, Altogen Labs has remained fully operational throughout the global disruption to research supply chains, continuing to deliver xenograft efficacy studies and pharmacology/toxicology packages on schedule.
Oncology programs do not pause. Cancer pathologies without a therapeutic solution have not disappeared, and sponsors advancing investigational new drugs (INDs) require a CRO partner capable of maintaining timelines, animal colonies, and data quality without interruption. Altogen Labs has met that standard continuously since 2009.
The company maintains one of the largest collections of in-house validated tumor models available from any independent preclinical CRO, including cell line-derived xenografts (CDX), patient-derived xenografts (PDX), syngeneic and allograft murine models, patient-derived cell cultures (PDC), patient-derived organoids (PDOrg), and new approach methodologies (NAMs). This breadth allows sponsors to select genetically and clinically relevant models rather than forcing a program into whichever model happens to be available.
Altogen Labs scientists perform acute, sub-chronic, and chronic toxicity studies for the assessment of drug safety, supported by comprehensive statistical and quantitative analysis of toxic effects in potential drug candidates. In vivo services for the preclinical discovery phase include teratoma formation and analysis, murine xenograft models across all major tumor types, pharmacokinetic (PK) and pharmacodynamic (PD) services, biodistribution and imaging studies, and tissue-targeted in vivo RNAi delivery.
All animal handling and maintenance at the Altogen Labs facility is IACUC-regulated and GLP-compliant, performed by experienced personnel who provide detailed experimental procedures, health reports, and an all-inclusive final report containing methods, results, discussion, raw data, and statistical analysis. One hundred percent of intellectual property generated in the course of a study belongs to the client.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research services and biology CRO services to pharmaceutical companies, biotechnology firms, and cancer research institutions worldwide. The company maintains an extensive portfolio of in-house validated xenograft models – CDX, PDX, syngeneic, organoids, and NAMs — and brings deep, sustained experience in efficacy xenograft studies and safety toxicology studies supporting IND applications and regulatory submissions.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Source citation: Business Wire, “Altogen Labs Preclinical Efficacy and In Vivo Toxicology Services,” May 19, 2020.